Bempedoic acid + ezetimibe
Bempedoic acid + ezetimibe has been studied in 7 papers since 2026: 5 observational studies in people, 2 reviews; 7 in the past year. The newest paper, Oct 26, 2026: “Real-world use of bempedoic acid in women and men: pooled 1-year follow-up data from the observational, prospective, real-world MILOS study in Austria, Belgium, Germany, Italy, and the United Kingdom”.
16 new papers in 30 daysSee all 35
“85% achieved <1.8 mmol/L, 68% achieved <1.4 mmol/L, and 39% achieved <1.0 mmol/L”
None of its findings points the other way.
- 3 independent labs in 3 countries
- Humans5
What did studies of Bempedoic acid + ezetimibe find?
3Studies of Bempedoic acid + ezetimibe measured 3 outcomes; the most studied are LDL-C (2 studies), LDL cholesterol (1) and ESC LDL-C target attainment (1).
LDL-C
downin humans2−36% reduction
2 studies
LDL-C
downin humans2−36% reduction
Bempedoic acid + ezetimibe decreases LDL-C in humans (dyslipidaemia) (-36.90% (95% CI: -44.65 to -29.15)).
“bempedoic acid plus ezetimibe (-36.90%; 95% CI: -44.65 to -29.15)”
Reviewdyslipidaemia
Endocrinology, diabetes & metabolism
Bempedoic acid + ezetimibe decreases LDL-C in humans (high-risk patients) (approximately 36.2% reduction).
“fixed-dose combination of bempedoic acid and ezetimibe produces an approximately 36.2% reduction in LDL-C in high-risk patients”
Reviewhigh-risk patients
Contemporary non-statin therapies for dyslipidemia management: achieving current lipid targets
Frontiers in medicine
LDL cholesterol
downin humans1
1 study
LDL cholesterol
downin humans1
Bempedoic acid + ezetimibe is linked with lower LDL cholesterol in humans (Compared with bempedoic acid alone, on stable background lipid-lowering therapy) (Median reduction 34.5% versus 20.1% with bempedoic acid alone; p=0.003).
“Median LDL-C reduction was significantly higher in patients starting BA+E (34.5%, IQR 13.2; 47.1), compared to those on BA alone”
HumansCompared with bempedoic acid alone, on stable background lipid-lowering therapyMedian follow-up of 6.5 monthsn = 132
Real-world efficacy of bempedoic acid: early insights from the BEMPENET Italian Registry
ESC Congress 2026 abstract
ESC LDL-C target attainment
upin humans1
1 study
ESC LDL-C target attainment
upin humans1
Bempedoic acid + ezetimibe is linked with higher ESC LDL-C target attainment in humans (secondary prevention receiving fixed-dose combination therapy) (85% achieved <1.8 mmol/L, 68% <1.4 mmol/L, 39% <1.0 mmol/L).
“85% achieved <1.8 mmol/L, 68% achieved <1.4 mmol/L, and 39% achieved <1.0 mmol/L”
Humanssecondary prevention receiving fixed-dose combination therapy
ESC Congress 2026 abstract